KDM4A and neoplasm: Animal studies presented a 4.4-fold lower tumor-initiating cell frequency by TACH101.394 In lung cancer, JMJD2 inhibition by either JMJD2 selective inhibitor ML324 or pan-JMJD inhibitor JIB04 could overcome cisplatin resistance, potentially by preventing ATR-Chk1 replication checkpoint.395 Furthermore, the combined treatment of JMJD2 inhibitors and LSD1 inhibitors may represent a more effective strategy for the enhancement of chemotherapy efficacy.396